Lantheus Medical Imaging (NSDQ:LNTH) parent company Lantheus Holdings announced the completion of its merger with Progenics Pharmaceuticals. Progenics, an oncology company developing medicines and artificial intelligence-based technologies for finding, fighting and following cancer, entered into a merger agreement with Lantheus that was first announced on Oct. 2, 2019. Get the full story at our sister site, MassDevice.
Lantheus today said it appointed Paul Blanchfield as chief commercial officer, effective immediately. Blanchfield will report to president and CEO Mary Anne Heino. “With his extensive operational experience and deep expertise in commercializing rare disease products, Paul will be a valuable addition to our executive leadership team as we execute our long-term growth strategy,” Heino […]